--- title: "New Research from Yale Finds Lacosamide May Help Manage Osteoarthritis Symptoms" url: https://noti.group/new-research-from-yale-finds-lacosamide-may-help-manage/ language: en publisher: "Noti Group" section: "Health" published: 2026-10-08T13:52:56.000Z updated: 2026-10-08T16:54:36.322Z id: 30605681-6da1-4319-9c9b-50e8507e498c source: "ScienceDaily Health https://www.sciencedaily.com/releases/2026/10/261006234528.htm" attribution: "Link to https://noti.group/new-research-from-yale-finds-lacosamide-may-help-manage/ and name Noti Group when you quote or summarize this story." --- # New Research from Yale Finds Lacosamide May Help Manage Osteoarthritis Symptoms A new study from Yale suggests that lacosamide, an FDA-approved medication for epilepsy, can reduce joint pain and reverse cartilage damage in patients with osteoarthritis when delivered directly into the joint. Millions of people worldwide live with osteoarthritis, a condition characterized by debilitating joint pain and stiffness that makes everyday activities increasingly challenging. Common treatments for osteoarthritis, such as over-the-counter medications and steroid injections, may provide temporary relief from symptoms but fail to prevent the underlying joint damage from progressing. This is where new research from Yale comes in, offering a promising alternative approach to managing the condition. The study's findings suggest that lacosamide, an FDA-approved medication used to treat epilepsy, can serve two purposes in osteoarthritis: reducing joint pain and reversing cartilage damage. When delivered directly into the joint using a specialized hydrogel, the effects were particularly strong. Osteoarthritis is often misunderstood as solely a wear-and-tear condition, but this oversimplifies the complex biology involved. Within a healthy joint, cells called chondrocytes maintain cartilage by balancing the creation of new tissue with the removal of old material. However, osteoarthritis disrupts this delicate balance. The disease causes cartilage to break down faster than it can be replaced, leading to bone-on-bone contact and eventual joint damage that may require reconstructive surgery in severe cases. Research has shown that osteoarthritis pain cannot be effectively managed by any currently approved medication from the U.S. Food and Drug Administration, which also fails to prevent cartilage breakdown. To address this issue, a team of researchers repurposed an existing epilepsy drug and combined it with a specialized gel designed to keep the medication localized within the joint. This innovative approach may offer sustained pain relief while preserving joint tissue, potentially replacing the need for addictive opioids. The study focuses on Nav1.7, a protein that acts as a sodium channel in cell membranes, controlling electrical signaling between cells. Initially thought to be primarily active in nerve cells responsible for transmitting pain signals, recent findings have revealed its significant presence in chondrocytes, which maintain cartilage health. In healthy joints, Nav1.7 activity is relatively low, but it surges significantly in osteoarthritis patients. This increased activity exacerbates pain signaling and prompts chondrocytes to degrade the cartilage they normally help preserve, leading to further joint damage. The protein's dual role in both pain sensation and cartilage deterioration makes Nav1.7 an intriguing target for therapeutic intervention, offering a potential solution that addresses multiple aspects of osteoarthritis simultaneously. The research team's findings suggest that targeting Nav1.7 could have a dual impact on osteoarthritis symptoms, addressing both pain sensation and cartilage deterioration simultaneously. To explore this potential, researchers tested existing medications that inhibit sodium channels, such as those used to treat epilepsy. Among these, lacosamide showed promising results in promoting cartilage repair at lower concentrations than its predecessors. Lacosamide's effects on cartilage were found to be highly dose-dependent, with an optimal range where the benefits of cartilage restoration and suppression of tissue breakdown were most pronounced. At this ideal concentration, cells began producing proteins essential for building new cartilage. The team also observed that lacosamide altered cell communication pathways by stimulating the release of two beneficial signaling proteins: HSP70 and midkine. This change in cellular behavior further supports the potential of lacosamide as a therapeutic agent for osteoarthritis. Further investigation is needed to fully understand the mechanisms behind lacosamide's effects on cartilage repair, but these findings offer an intriguing lead for developing new treatments that address multiple aspects of osteoarthritis simultaneously. The combination of HSP70 and midkine proteins appears to create an environment that favors cartilage maintenance by regulating inflammation and protecting joint tissue from degeneration. These proteins work together to establish conditions that allow for the extension of a drug's effects beyond individual cells, influencing the entire tissue instead. To effectively deliver lacosamide directly into the affected joint, researchers investigated intra-articular injection, bypassing oral treatment which can cause unwanted side effects elsewhere in the body. The knee joint poses a challenge due to its natural ability to clear out liquids injected into it within hours, likened to a "leaky bucket" by Liu, making it difficult for medication to remain effective over time. To address this issue, researchers developed a smart hydrogel made from Collagen II that remains liquid at cool temperatures and becomes firm upon reaching body temperature, serving as a storage site for lacosamide while gradually releasing the medication over several weeks. The innovative hydrogel developed by researchers is designed to act as a local reservoir for lacosamide, releasing it slowly over time in the exact location where it's needed most. This means that patients would only need to receive one injection every four weeks, rather than taking daily pills. This approach has been shown to be highly effective in preventing cartilage loss, with results indicating that a single injection of the gel is more effective than taking an oral dose every day. The researchers are optimistic about the potential for this treatment to provide long-lasting relief from osteoarthritis symptoms. One major advantage of using lacosamide is that it's already been approved by regulatory authorities for use in people, which could speed up the process of moving into clinical trials with osteoarthritis patients. This means that researchers can bypass some of the early stages of testing and focus on evaluating its effectiveness in treating this specific condition. The fact that lacosamide has also been tested in humans with certain nerve-related pain conditions gives the researchers added confidence that their approach could lead to meaningful pain relief for patients. The results from these studies suggest that the effects seen in laboratory experiments may translate well into real-world applications. As medicine continues to evolve, this research reflects a growing trend of combining established drugs with advanced biomaterials to precisely control where and how treatments are delivered. If successful, this approach could ultimately reduce the number of medical procedures patients need, minimize side effects, and provide longer-lasting protection against joint damage. The latest research from Yale School of Medicine has made significant strides in osteoarthritis treatment by repurposing a medication originally developed for epilepsy. This innovative approach aims to target the root cause of joint damage rather than just controlling its symptoms. By leveraging the drug's existing approval and efficacy, researchers are working towards creating a system that allows the medicine to work more effectively at the site of inflammation in the joints. This novel strategy seeks to move beyond mere symptom management and instead modify the underlying disease process. Ultimately, this effort has the potential to revolutionize osteoarthritis treatment. --- Source: [ScienceDaily Health](https://www.sciencedaily.com/releases/2026/10/261006234528.htm) Published by Noti Group: https://noti.group/new-research-from-yale-finds-lacosamide-may-help-manage/